Project Grant R44CA261318
- The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
- This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,990 to Scorpido Photonics aims to develop a prototype endoscope-based diagnostic system for rapid, non-invasive detection of microscopic tumors. The project integrates plasmonic nanobubble sensors into a medical device platform and standard endoscope to enable instant, optical detection of cancerous tissues during lung cancer diagnostic procedures. The key product is a...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,295,800 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a novel optical endoscope that does not require mechanical rotation to perform 360-degree in vivo imaging. The project aims to design and fabricate a metasurface that can...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $549,958 to the University of California Irvine (UC Irvine) to develop a meta-optical fiber endoscope (MOFE) device. The MOFE aims to significantly reduce the size of endoscopic imaging components, enabling less invasive medical procedures and expanding the range of biomedical applications. Key objectives include integrating optical metasurfaces...
- The National Science Foundation awarded Pensievision, Inc. $255,947 under the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an endoscopic 3D imaging system for evaluating cancers and disorders of the esophagus and pharynx. The Small Business Innovation Research Phase I project will combine liquid lens technology, artificial intelligence software, and astronomical imaging techniques to generate three-dimensional images of early-stage esophageal and throat tumors....
- This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $294,505 to support the development and commercialization of a targeted fluorescence dye for intraoperative imaging and precision surgical treatment of head and neck cancer (HNC). The goal is to create a small peptide-based fluorescent probe that can specifically stain HNC tumors to assist surgeons in identifying tumors...
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,205,290 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to the Massachusetts Eye And Ear Infirmary. The grant supports the development of a fluorescence lifetime-based intraoperative imaging system to enhance visualization and real-time feedback for sarcoma surgeries. The project aims to create new tools that can accurately detect...
- Modendo Inc. received a $256,000 Small Business Innovation Research Phase I Project Grant from the National Science Foundation to develop an ultrathin endomicroscope. The grant was awarded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to advance science and engineering research leading to breakthrough technologies. Specifically, the funding will support Modendo's development of a new class of minimally invasive endoscope probes with diameters as small as 100...
ENDOSCOPE DEVELOPMENT FOR THE CLINICAL USE OF NEAR INFRARED FLUORESCENCE MOLECULAR PROBES IN THE GI TRACT - MINIMALLY-INVASIVE OPTICAL IMAGING IS BEING ADVANCED BY MOLECULAR PROBES THAT ENHANCE CONTRAST USING FLUORESCENCE. THE APPLICATIONS IN CANCER IMAGING ARE VERY BROAD, RANGING FROM EARLY DIAGNOSIS OF CANCER TO THE GUIDING OF INTERVENTIONS, SUCH AS BIOPSY. THE HIGH-SENSITIVITY AFFORDED BY WIDE-FIELD FLUORESCENCE IMAGING USING SCANNING LASER LIGHT IS BEING DEVELOPED FOR THESE BROAD APPLICATIONS. THE PLATFORM TECHNOLOGY IS THE SFE - SCANNING FIBER ENDOSCOPE, WHICH PLACES A SUB-1-MM SCANNER AT THE TIP OF A HIGHLY FLEXIBLE SHAFT. BECAUSE SEVERAL DIFFERENT LASER WAVELENGTHS CAN BE MIXED AND SCANNED TOGETHER, FULL-COLOR REFLECTANCE IMAGING WILL BE COMBINED WITH NEAR INFRARED (NIR) FLUORESCENCE IMAGING IN A 4-CHANNEL MULTIMODAL SFE. THE GOAL OF THIS PROJECT IS TO DEVELOP A PROTOTYPE VERAVANTI 4-CHANNEL MULTIMODAL SFE (MMSFE) FOR A SPECIFIC CANCER IMAGING APPLICATION THAT CAN HAVE SIGNIFICANT IMPACT IN EARLY DETECTION AND ENDOSCOPIC TREATMENT OF ESOPHAGEAL CANCER. VERAVANTI IS A START-UP COMPANY LOCATED IN REDMOND, WASHINGTON AND IS FOUNDED AND STAFFED WITH ENGINEERING GRADUATES FROM THE UNIVERSITY OF WASHINGTON (UW), WHERE THE SFE WAS INVENTED AND TESTED IN PILOT CLINICAL TRIALS. VERAVANTI HAS EXCLUSIVE LICENSE TO COMMERCIALIZE THE SFE TECHNOLOGY FOR MEDICAL IMAGING AND A 3- CHANNEL FULL COLOR SFE (USING RED, GREEN, AND BLUE REFLECTANCE) IS ALREADY IN PILOT MANUFACTURING AND TESTING. THIS PROJECT WILL RAPIDLY TRANSLATE THE 4-CHANNEL MMSFE TECHNOLOGY INTO A SPECIFIC PRODUCT FOR FLUORESCENTLY GUIDING ENDOSCOPIC INTERVENTIONS IN THE GI TRACT. FURTHERMORE, THE VERAVANTI MMSFE WILL BE DESIGNED FOR EFFICIENT MANUFACTURING IN A MODULAR FORMAT WITH REDUCED PART NUMBERS AND EXPECTED LOWER COST. THE APPLICATION IS USING NIR FLUORESCENCE MOLECULAR PROBES THAT WERE DEVELOPED AT THE UNIVERSITY OF MICHIGAN (UM) THAT BIND TO HIGH GRADE DYSPLASIA (HGD) AND NEOPLASTIC CELLS OF ESOPHAGEAL ADENOCARCINOMA (EAC). THE MMSFE PRODUCT IS INTRODUCED THROUGH THE WORKING CHANNEL OF A CONVENTIONAL ENDOSCOPE TO IDENTIFY REGIONS OF THE LOWER ESOPHAGUS THAT ARE OVER-EXPRESSING EGFR AND ERBB2, WHICH ARE TRANSMEMBRANE TYROSINE KINASE RECEPTORS THAT STIMULATE EPITHELIAL CELL GROWTH, PROLIFERATION, AND DIFFERENTIATION. OVEREXPRESSION OF THESE TARGETS REFLECTS AN INCREASE IN BIOLOGICAL AGGRESSIVENESS AND HIGHER RISK FOR PROGRESSION TO BARRETT'S ESOPHAGUS, HGD, AND EAC. THE DESIGN OF THE MMSFE DIAGNOSTIC ALGORITHM IS BASED ON THE HIGH CORRELATION OF THE FLUORESCENCE LESION TARGET-TO-BACKGROUND MEASUREMENT IN COLLABORATION WITH UW AND UM. ADDITIONAL MMSFE GUIDED TOOLS WILL BE DEVELOPED FOR MORE ACCURATE ENDOSCOPIC INTERVENTIONS USING NIR FLUORESCENCE MOLECULAR PROBES. BOTH SOFTWARE AND HARDWARE WILL BE FABRICATED AND TESTED FOR THE START OF A MULTISITE CLINICAL TRIAL USING THE MMSFE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/16/24 | ||
| Not listed | $0 | 9/15/23 | ||
| Not listed | $1.0m | 8/25/22 | ||
| Not listed | $1.0m | 8/25/22 | ||
| Not listed | $993.2k | 9/23/21 |